Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. PRO: maintenance therapy is superior to episodic therapy.
Lichtenstein
Gary R
GR
Department of Medicine, Hospital of the University of Pennsylvania, School of Medicine, PA, USA.
D000906:Antibodies / Q000276:immunology; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use; D003424:Crohn Disease / Q000188:drug therapy*; D004334:Drug Administration Schedule; D016527:Drug Costs; D005765:Gastrointestinal Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D000069285:Infliximab
D000906:Antibodies; D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D007155:Immunologic Factors; D000069285:Infliximab